OTCMKTS:CYYNF Cynata Therapeutics (CYYNF) Stock Price, News & Analysis $0.19 0.00 (0.00%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChart About Cynata Therapeutics Stock (OTCMKTS:CYYNF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cynata Therapeutics alerts:Sign Up Key Stats Today's Range$0.19▼$0.1950-Day Range$0.19▼$0.1952-Week Range$0.11▼$0.19VolumeN/AAverage Volume200 shsMarket Capitalization$27.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.Read More… 625,000% Gain (Ad)The recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.>> Dive into the Workshop Here Receive CYYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYYNF Stock News HeadlinesAlive and Kicking: Watch this space on controversy-free stem-cell therapy trials, says CynataSeptember 5, 2024 | msn.comCynata Therapeutics Limited (CYYNF)August 29, 2024 | au.finance.yahoo.comThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.October 31, 2024 | Behind the Markets (Ad)Cynata Therapeutics treats first patient in aGvHD drug trialMarch 6, 2024 | msn.comFirst Patient Treated in Phase 2 GvHD TrialMarch 4, 2024 | finance.yahoo.comVYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and Vor Biopharma (VOR)August 11, 2023 | markets.businessinsider.comSee More Headlines CYYNF Stock Analysis - Frequently Asked Questions How have CYYNF shares performed this year? Cynata Therapeutics' stock was trading at $0.0720 at the start of the year. Since then, CYYNF stock has increased by 163.9% and is now trading at $0.19. View the best growth stocks for 2024 here. How do I buy shares of Cynata Therapeutics? Shares of CYYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today10/31/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Sanitary paper products Sub-IndustryN/A Current SymbolOTCMKTS:CYYNF CUSIPN/A CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares143,277,000Free FloatN/AMarket Cap$27.22 million OptionableNot Optionable Beta0.43 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:CYYNF) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.